Trials / Recruiting
RecruitingNCT06718634
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Relapsed or Refractory Lymphoid Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter, dose-escalation and extended-enrollment, nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for injection in relapsed or refractory lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-M08D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
Timeline
- Start date
- 2025-01-02
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2024-12-05
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06718634. Inclusion in this directory is not an endorsement.